Skip to main content

Table 2 Characteristics of the cell product administered

From: Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up

Patient Weight (Kg) Dosage (× 106 per Kg) Phase Days of expansion Viability (% of viable cells) Karyotype In vitro differentiation
1 88 1.5 25 95 46, XY [17] Yes
2 82 1.5 18 91,8 46, XX [22] Yes
3 75.3 1.06 18 92 No Metaphases Yes
4 75 1.33 26 97 46, XY [21] Yes
5 94 1.5 20 94 46, XY [20] Yes
6 68 1.5 26 97 46, XX [20] Yes
7 98 1.5 21 94 46, XY [20] Yes
8 74 1.5 20 95 No Metaphases No
9 51 1.5 21 94 46, XX [15] Yes
10 84 1.5 26 100 46, XX [20] Yes
11 64 1.5 21 95 46, XX [21] Yes